<DOC>
	<DOCNO>NCT00004072</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine O6-benzylguanine carmustine treat patient previously untreated , refractory , relapse multiple myeloma .</brief_summary>
	<brief_title>O6-benzylguanine And Carmustine Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate efficacy O6-benzylguanine combine carmustine patient previously untreated refractory multiple myeloma . - Assess effect O6-benzylguanine bone marrow myeloma cell patient population . OUTLINE : Patients receive O6-benzylguanine IV 60 minute follow 1 hour later carmustine IV 60 minute . Courses repeat every 6 week absence disease progression unacceptable toxicity . Patients receive 2 additional course beyond attainment best response ( partial complete response stable plateau disease ) . Patients follow every 2 month . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm progressive multiple myeloma , meet 1 follow criterion : Previously untreated Primary refractory Relapsing disease Major criterion : Plasmacytomas tissue biopsy Bone marrow plasmacytosis great 30 % plasma cell Monoclonal globulin spike serum electrophoresis Greater 3.5 g/dL G peak great 2.0 g A peak Greater 1.0 g/24 hour kappa lambda light chain excretion urine electrophoresis absence amyloidosis Minor criterion : 10 % 30 % bone marrow plasmacytosis ( criterion A ) Presence monoclonal globulin spike less level major criterion ( criterion B ) Lytic bone lesion ( criterion C ) IgM le 50 mg/dL , IgA le 100 mg/dL , IgG le 600 mg/dL ( criterion D ) Must meet one follow : A minimum 1 major criterion 1 minor criterion 3 minor criterion , include criterion A B PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC great 3,000/mm^3 Platelet count great 100,000/mm^3 Absolute neutrophil count great 1,500/mm^3 Hemoglobin great 9 g/dL ( transfusion allow ) Hepatic : Bilirubin le 1.5 mg/dL AST/ALT le 2 time normal Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance great 60 mL/min Calcium le 14 mg/dL Pulmonary : No prior concurrent active , symptomatic respiratory disease Corrected DLCO least 60 % predict Other : Controlled diabetes mellitus allow Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 1 prior chemotherapy regimen contain alkylating agent multiple myeloma At least 4 week since prior chemotherapy Endocrine therapy : Prior corticosteroid multiple myeloma allow Radiotherapy : No prior pelvic radiotherapy radiotherapy 25 % bone marrow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>